APO Research
Talk to an analyst

APO RESEARCH · REPORT

Calcineurin Inhibitor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Calcineurin Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchCalcineurin Inhibitor Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Calcineurin Inhibitor Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Calcineurin Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Calcineurin Inhibitor Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Calcineurin Inhibitor Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Calcineurin Inhibitor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Calcineurin Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Calcineurin Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Calcineurin Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Calcineurin Inhibitor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Calcineurin Inhibitor Drug include Sun Pharmaceutical Industries, Inc, Johnson & Johnson, Novartis AG, Mylan N.V., Pfizer Inc, AbbVie Inc, Wockhardt, Teva Pharmaceuticals Industries Inc, Veloxis Pharmaceuticals, Inc, and Mayne Pharma Group Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Calcineurin Inhibitor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Calcineurin Inhibitor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Calcineurin Inhibitor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Calcineurin Inhibitor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Calcineurin Inhibitor Drug Segment by Company

Sun Pharmaceutical Industries, Inc

Johnson & Johnson

Novartis AG

Mylan N.V.

Pfizer Inc

AbbVie Inc

Wockhardt, Teva Pharmaceuticals Industries Inc

Veloxis Pharmaceuticals, Inc,

Mayne Pharma Group Limited

Leo Pharma A/S

Glenmark Pharmaceuticals Ltd

Dr. Reddy's Laboratories Ltd

Astellas Pharma Inc

Apotex Inc

Amneal Pharmaceuticals Inc

Allergan

Calcineurin Inhibitor Drug Segment by Type

Tacrolimus

Cyclosporine

Pimecrolimus

Others

Calcineurin Inhibitor Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Calcineurin Inhibitor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Calcineurin Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Calcineurin Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Calcineurin Inhibitor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Calcineurin Inhibitor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Calcineurin Inhibitor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Calcineurin Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Calcineurin Inhibitor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Calcineurin Inhibitor Drug Industry Trends Table 2. Calcineurin Inhibitor Drug Industry Drivers Table 3. Calcineurin Inhibitor Drug Industry Opportunities and Challenges Table 4. Calcineurin Inhibitor Drug Industry Restraints Table 5. Global Calcineurin Inhibitor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Calcineurin Inhibitor Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Calcineurin Inhibitor Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Calcineurin Inhibitor Drug Sales Market Share by Manufacturers Table 9. Global Calcineurin Inhibitor Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Calcineurin Inhibitor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Calcineurin Inhibitor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Calcineurin Inhibitor Drug Manufacturers, Product Type & Application Table 13. Global Calcineurin Inhibitor Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Calcineurin Inhibitor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tacrolimus Table 17. Major Manufacturers of Cyclosporine Table 18. Major Manufacturers of Pimecrolimus Table 19. Major Manufacturers of Others Table 20. Global Calcineurin Inhibitor Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Calcineurin Inhibitor Drug Sales by Type (2021-2026) & (k units) Table 22. Global Calcineurin Inhibitor Drug Sales by Type (2027-2032) & (k units) Table 23. Global Calcineurin Inhibitor Drug Sales Market Share by Type (2021-2026) Table 24. Global Calcineurin Inhibitor Drug Sales Market Share by Type (2027-2032) Table 25. Global Calcineurin Inhibitor Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Calcineurin Inhibitor Drug Revenue by Type (2021-2026) & (k units) Table 27. Global Calcineurin Inhibitor Drug Revenue by Type (2027-2032) & (k units) Table 28. Global Calcineurin Inhibitor Drug Revenue Market Share by Type (2021-2026) Table 29. Global Calcineurin Inhibitor Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Pharmacies Table 31. Major Manufacturers of Online Pharmacies Table 32. Major Manufacturers of Retail Pharmacies Table 33. Global Calcineurin Inhibitor Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Calcineurin Inhibitor Drug Sales by Application (2021-2026) & (k units) Table 35. Global Calcineurin Inhibitor Drug Sales by Application (2027-2032) & (k units) Table 36. Global Calcineurin Inhibitor Drug Sales Market Share by Application (2021-2026) Table 37. Global Calcineurin Inhibitor Drug Sales Market Share by Application (2027-2032) Table 38. Global Calcineurin Inhibitor Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Calcineurin Inhibitor Drug Revenue by Application (2021-2026) & (k units) Table 40. Global Calcineurin Inhibitor Drug Revenue by Application (2027-2032) & (k units) Table 41. Global Calcineurin Inhibitor Drug Revenue Market Share by Application (2021-2026) Table 42. Global Calcineurin Inhibitor Drug Revenue Market Share by Application (2027-2032) Table 43. Global Calcineurin Inhibitor Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Calcineurin Inhibitor Drug Sales by Region (2021-2026) & (k units) Table 45. Global Calcineurin Inhibitor Drug Sales Market Share by Region (2021-2026) Table 46. Global Calcineurin Inhibitor Drug Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Calcineurin Inhibitor Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Calcineurin Inhibitor Drug Sales by Country (2021-2026) & (k units) Table 50. North America Calcineurin Inhibitor Drug Sales by Country (2027-2032) & (k units) Table 51. Europe Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Calcineurin Inhibitor Drug Sales by Country (2021-2026) & (k units) Table 53. Europe Calcineurin Inhibitor Drug Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Calcineurin Inhibitor Drug Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Calcineurin Inhibitor Drug Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Calcineurin Inhibitor Drug Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Calcineurin Inhibitor Drug Sales by Country (2027-2032) & (k units) Table 60. Global Calcineurin Inhibitor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Calcineurin Inhibitor Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Calcineurin Inhibitor Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Calcineurin Inhibitor Drug Revenue Market Share by Region (2021-2026) Table 64. Global Calcineurin Inhibitor Drug Revenue Market Share by Region (2027-2032) Table 65. Sun Pharmaceutical Industries, Inc Company Information Table 66. Sun Pharmaceutical Industries, Inc Business Overview Table 67. Sun Pharmaceutical Industries, Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sun Pharmaceutical Industries, Inc Calcineurin Inhibitor Drug Product Portfolio Table 69. Sun Pharmaceutical Industries, Inc Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Calcineurin Inhibitor Drug Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis AG Calcineurin Inhibitor Drug Product Portfolio Table 79. Novartis AG Recent Development Table 80. Mylan N.V. Company Information Table 81. Mylan N.V. Business Overview Table 82. Mylan N.V. Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mylan N.V. Calcineurin Inhibitor Drug Product Portfolio Table 84. Mylan N.V. Recent Development Table 85. Pfizer Inc Company Information Table 86. Pfizer Inc Business Overview Table 87. Pfizer Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Pfizer Inc Calcineurin Inhibitor Drug Product Portfolio Table 89. Pfizer Inc Recent Development Table 90. AbbVie Inc Company Information Table 91. AbbVie Inc Business Overview Table 92. AbbVie Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AbbVie Inc Calcineurin Inhibitor Drug Product Portfolio Table 94. AbbVie Inc Recent Development Table 95. Wockhardt, Teva Pharmaceuticals Industries Inc Company Information Table 96. Wockhardt, Teva Pharmaceuticals Industries Inc Business Overview Table 97. Wockhardt, Teva Pharmaceuticals Industries Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Wockhardt, Teva Pharmaceuticals Industries Inc Calcineurin Inhibitor Drug Product Portfolio Table 99. Wockhardt, Teva Pharmaceuticals Industries Inc Recent Development Table 100. Veloxis Pharmaceuticals, Inc, Company Information Table 101. Veloxis Pharmaceuticals, Inc, Business Overview Table 102. Veloxis Pharmaceuticals, Inc, Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Veloxis Pharmaceuticals, Inc, Calcineurin Inhibitor Drug Product Portfolio Table 104. Veloxis Pharmaceuticals, Inc, Recent Development Table 105. Mayne Pharma Group Limited Company Information Table 106. Mayne Pharma Group Limited Business Overview Table 107. Mayne Pharma Group Limited Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Mayne Pharma Group Limited Calcineurin Inhibitor Drug Product Portfolio Table 109. Mayne Pharma Group Limited Recent Development Table 110. Leo Pharma A/S Company Information Table 111. Leo Pharma A/S Business Overview Table 112. Leo Pharma A/S Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Leo Pharma A/S Calcineurin Inhibitor Drug Product Portfolio Table 114. Leo Pharma A/S Recent Development Table 115. Glenmark Pharmaceuticals Ltd Company Information Table 116. Glenmark Pharmaceuticals Ltd Business Overview Table 117. Glenmark Pharmaceuticals Ltd Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Glenmark Pharmaceuticals Ltd Calcineurin Inhibitor Drug Product Portfolio Table 119. Glenmark Pharmaceuticals Ltd Recent Development Table 120. Dr. Reddy's Laboratories Ltd Company Information Table 121. Dr. Reddy's Laboratories Ltd Business Overview Table 122. Dr. Reddy's Laboratories Ltd Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Dr. Reddy's Laboratories Ltd Calcineurin Inhibitor Drug Product Portfolio Table 124. Dr. Reddy's Laboratories Ltd Recent Development Table 125. Astellas Pharma Inc Company Information Table 126. Astellas Pharma Inc Business Overview Table 127. Astellas Pharma Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Astellas Pharma Inc Calcineurin Inhibitor Drug Product Portfolio Table 129. Astellas Pharma Inc Recent Development Table 130. Apotex Inc Company Information Table 131. Apotex Inc Business Overview Table 132. Apotex Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Apotex Inc Calcineurin Inhibitor Drug Product Portfolio Table 134. Apotex Inc Recent Development Table 135. Amneal Pharmaceuticals Inc Company Information Table 136. Amneal Pharmaceuticals Inc Business Overview Table 137. Amneal Pharmaceuticals Inc Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Amneal Pharmaceuticals Inc Calcineurin Inhibitor Drug Product Portfolio Table 139. Amneal Pharmaceuticals Inc Recent Development Table 140. Allergan Company Information Table 141. Allergan Business Overview Table 142. Allergan Calcineurin Inhibitor Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Allergan Calcineurin Inhibitor Drug Product Portfolio Table 144. Allergan Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Calcineurin Inhibitor Drug Distributors List Table 148. Calcineurin Inhibitor Drug Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Calcineurin Inhibitor Drug Product Image Figure 2. Global Calcineurin Inhibitor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Calcineurin Inhibitor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Calcineurin Inhibitor Drug Sales (2021-2032) & (k units) Figure 5. Global Calcineurin Inhibitor Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Calcineurin Inhibitor Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tacrolimus Image Figure 9. Cyclosporine Image Figure 10. Pimecrolimus Image Figure 11. Others Image Figure 12. Global Calcineurin Inhibitor Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Calcineurin Inhibitor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Calcineurin Inhibitor Drug Sales Market Share by Type (2021-2032) Figure 15. Global Calcineurin Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Calcineurin Inhibitor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Calcineurin Inhibitor Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Pharmacies Image Figure 19. Online Pharmacies Image Figure 20. Retail Pharmacies Image Figure 21. Global Calcineurin Inhibitor Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Calcineurin Inhibitor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Calcineurin Inhibitor Drug Sales Market Share by Application (2021-2032) Figure 24. Global Calcineurin Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Calcineurin Inhibitor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Calcineurin Inhibitor Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Calcineurin Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Calcineurin Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Calcineurin Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 41. China Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Calcineurin Inhibitor Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Calcineurin Inhibitor Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Calcineurin Inhibitor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Calcineurin Inhibitor Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Calcineurin Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Calcineurin Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Calcineurin Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Calcineurin Inhibitor Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Calcineurin Inhibitor Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Calcineurin Inhibitor Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tacrolimus
  • Cyclosporine
  • Pimecrolimus
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharmaceutical Industries, Inc
  • Johnson & Johnson
  • Novartis AG
  • Mylan N.V.
  • Pfizer Inc
  • AbbVie Inc
  • Wockhardt, Teva Pharmaceuticals Industries Inc
  • Veloxis Pharmaceuticals, Inc,
  • Mayne Pharma Group Limited
  • Leo Pharma A/S
  • Glenmark Pharmaceuticals Ltd
  • Dr. Reddy's Laboratories Ltd
  • Astellas Pharma Inc
  • Apotex Inc
  • Amneal Pharmaceuticals Inc
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Calcineurin Inhibitor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Calcineurin Inhibitor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Calcineurin Inhibitor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Calcineurin Inhibitor Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Calcineurin Inhibitor Drug Market Dynamics
  1. 2.1 Calcineurin Inhibitor Drug Industry Trends
  2. 2.2 Calcineurin Inhibitor Drug Industry Drivers
  3. 2.3 Calcineurin Inhibitor Drug Industry Opportunities and Challenges
  4. 2.4 Calcineurin Inhibitor Drug Industry Restraints
3 Calcineurin Inhibitor Drug Market by Manufacturers
  1. 3.1 Global Calcineurin Inhibitor Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Calcineurin Inhibitor Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Calcineurin Inhibitor Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Calcineurin Inhibitor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Calcineurin Inhibitor Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Calcineurin Inhibitor Drug Manufacturers, Product Type & Application
  7. 3.7 Global Calcineurin Inhibitor Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Calcineurin Inhibitor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Calcineurin Inhibitor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Calcineurin Inhibitor Drug Tier 1, Tier 2, and Tier 3
4 Calcineurin Inhibitor Drug Market by Type
  1. 4.1 Calcineurin Inhibitor Drug Type Introduction
  2. 4.1.1 Tacrolimus
  3. 4.1.2 Cyclosporine
  4. 4.1.3 Pimecrolimus
  5. 4.1.4 Others
  6. 4.2 Global Calcineurin Inhibitor Drug Sales by Type
  7. 4.2.1 Global Calcineurin Inhibitor Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Calcineurin Inhibitor Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Calcineurin Inhibitor Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Calcineurin Inhibitor Drug Revenue by Type
  11. 4.3.1 Global Calcineurin Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Calcineurin Inhibitor Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Calcineurin Inhibitor Drug Revenue Market Share by Type (2021-2032)
5 Calcineurin Inhibitor Drug Market by Application
  1. 5.1 Calcineurin Inhibitor Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Calcineurin Inhibitor Drug Sales by Application
  6. 5.2.1 Global Calcineurin Inhibitor Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Calcineurin Inhibitor Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Calcineurin Inhibitor Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Calcineurin Inhibitor Drug Revenue by Application
  10. 5.3.1 Global Calcineurin Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Calcineurin Inhibitor Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Calcineurin Inhibitor Drug Revenue Market Share by Application (2021-2032)
6 Global Calcineurin Inhibitor Drug Sales by Region
  1. 6.1 Global Calcineurin Inhibitor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Calcineurin Inhibitor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Calcineurin Inhibitor Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Calcineurin Inhibitor Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Calcineurin Inhibitor Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Calcineurin Inhibitor Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Calcineurin Inhibitor Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Calcineurin Inhibitor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Calcineurin Inhibitor Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Calcineurin Inhibitor Drug Revenue by Region
  1. 7.1 Global Calcineurin Inhibitor Drug Revenue by Region
  2. 7.1.1 Global Calcineurin Inhibitor Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Calcineurin Inhibitor Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Calcineurin Inhibitor Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Calcineurin Inhibitor Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Calcineurin Inhibitor Drug Revenue (2021-2032)
  8. 7.2.2 North America Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Calcineurin Inhibitor Drug Revenue (2021-2032)
  11. 7.3.2 Europe Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Calcineurin Inhibitor Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Calcineurin Inhibitor Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Calcineurin Inhibitor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceutical Industries, Inc
  2. 8.1.1 Sun Pharmaceutical Industries, Inc Company Information
  3. 8.1.2 Sun Pharmaceutical Industries, Inc Business Overview
  4. 8.1.3 Sun Pharmaceutical Industries, Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceutical Industries, Inc Calcineurin Inhibitor Drug Product Portfolio
  6. 8.1.5 Sun Pharmaceutical Industries, Inc Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Calcineurin Inhibitor Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Calcineurin Inhibitor Drug Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 Mylan N.V.
  20. 8.4.1 Mylan N.V. Company Information
  21. 8.4.2 Mylan N.V. Business Overview
  22. 8.4.3 Mylan N.V. Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan N.V. Calcineurin Inhibitor Drug Product Portfolio
  24. 8.4.5 Mylan N.V. Recent Developments
  25. 8.5 Pfizer Inc
  26. 8.5.1 Pfizer Inc Company Information
  27. 8.5.2 Pfizer Inc Business Overview
  28. 8.5.3 Pfizer Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc Calcineurin Inhibitor Drug Product Portfolio
  30. 8.5.5 Pfizer Inc Recent Developments
  31. 8.6 AbbVie Inc
  32. 8.6.1 AbbVie Inc Company Information
  33. 8.6.2 AbbVie Inc Business Overview
  34. 8.6.3 AbbVie Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Inc Calcineurin Inhibitor Drug Product Portfolio
  36. 8.6.5 AbbVie Inc Recent Developments
  37. 8.7 Wockhardt, Teva Pharmaceuticals Industries Inc
  38. 8.7.1 Wockhardt, Teva Pharmaceuticals Industries Inc Company Information
  39. 8.7.2 Wockhardt, Teva Pharmaceuticals Industries Inc Business Overview
  40. 8.7.3 Wockhardt, Teva Pharmaceuticals Industries Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt, Teva Pharmaceuticals Industries Inc Calcineurin Inhibitor Drug Product Portfolio
  42. 8.7.5 Wockhardt, Teva Pharmaceuticals Industries Inc Recent Developments
  43. 8.8 Veloxis Pharmaceuticals, Inc,
  44. 8.8.1 Veloxis Pharmaceuticals, Inc, Company Information
  45. 8.8.2 Veloxis Pharmaceuticals, Inc, Business Overview
  46. 8.8.3 Veloxis Pharmaceuticals, Inc, Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Veloxis Pharmaceuticals, Inc, Calcineurin Inhibitor Drug Product Portfolio
  48. 8.8.5 Veloxis Pharmaceuticals, Inc, Recent Developments
  49. 8.9 Mayne Pharma Group Limited
  50. 8.9.1 Mayne Pharma Group Limited Company Information
  51. 8.9.2 Mayne Pharma Group Limited Business Overview
  52. 8.9.3 Mayne Pharma Group Limited Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mayne Pharma Group Limited Calcineurin Inhibitor Drug Product Portfolio
  54. 8.9.5 Mayne Pharma Group Limited Recent Developments
  55. 8.10 Leo Pharma A/S
  56. 8.10.1 Leo Pharma A/S Company Information
  57. 8.10.2 Leo Pharma A/S Business Overview
  58. 8.10.3 Leo Pharma A/S Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Leo Pharma A/S Calcineurin Inhibitor Drug Product Portfolio
  60. 8.10.5 Leo Pharma A/S Recent Developments
  61. 8.11 Glenmark Pharmaceuticals Ltd
  62. 8.11.1 Glenmark Pharmaceuticals Ltd Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Ltd Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Ltd Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Ltd Calcineurin Inhibitor Drug Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Ltd Recent Developments
  67. 8.12 Dr. Reddy's Laboratories Ltd
  68. 8.12.1 Dr. Reddy's Laboratories Ltd Company Information
  69. 8.12.2 Dr. Reddy's Laboratories Ltd Business Overview
  70. 8.12.3 Dr. Reddy's Laboratories Ltd Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dr. Reddy's Laboratories Ltd Calcineurin Inhibitor Drug Product Portfolio
  72. 8.12.5 Dr. Reddy's Laboratories Ltd Recent Developments
  73. 8.13 Astellas Pharma Inc
  74. 8.13.1 Astellas Pharma Inc Company Information
  75. 8.13.2 Astellas Pharma Inc Business Overview
  76. 8.13.3 Astellas Pharma Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Inc Calcineurin Inhibitor Drug Product Portfolio
  78. 8.13.5 Astellas Pharma Inc Recent Developments
  79. 8.14 Apotex Inc
  80. 8.14.1 Apotex Inc Company Information
  81. 8.14.2 Apotex Inc Business Overview
  82. 8.14.3 Apotex Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Apotex Inc Calcineurin Inhibitor Drug Product Portfolio
  84. 8.14.5 Apotex Inc Recent Developments
  85. 8.15 Amneal Pharmaceuticals Inc
  86. 8.15.1 Amneal Pharmaceuticals Inc Company Information
  87. 8.15.2 Amneal Pharmaceuticals Inc Business Overview
  88. 8.15.3 Amneal Pharmaceuticals Inc Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Amneal Pharmaceuticals Inc Calcineurin Inhibitor Drug Product Portfolio
  90. 8.15.5 Amneal Pharmaceuticals Inc Recent Developments
  91. 8.16 Allergan
  92. 8.16.1 Allergan Company Information
  93. 8.16.2 Allergan Business Overview
  94. 8.16.3 Allergan Calcineurin Inhibitor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Allergan Calcineurin Inhibitor Drug Product Portfolio
  96. 8.16.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Calcineurin Inhibitor Drug Value Chain Analysis
  2. 9.1.1 Calcineurin Inhibitor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Calcineurin Inhibitor Drug Production Mode & Process
  6. 9.2 Calcineurin Inhibitor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Calcineurin Inhibitor Drug Distributors
  9. 9.2.3 Calcineurin Inhibitor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst